When would you ever choose cisplatin over carboplatin in extensive stage small cell lung cancer?

I prefer carboplatin over cisplatin in ES SCLC as there does not seem to be proven benefit and there is certainly higher risk for toxicity. There was a recent report at ASCO with similar findings. I reserve cisplatin for limited stage disease with concurrent radiation or as adjuvant therapy in cases of resected SCLC (albeit uncommon). IMpower133 made things pretty straightforward since only carboplatin was studied with etoposide +/- atezolizumab. However, CASPIAN did include cisplatin as a treat...